Bolt Biotherapeutics, Inc. (BOLT)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$13.4M
Cash & Equivalents
$8.0M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$7M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2027-05-01 Phase2 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06921837 A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer PHASE2 Recruiting 122

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for BOLT.

SEC EDGAR Filings

All SEC filings for Bolt Biotherapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.